Azitra, Inc. Addresses False Report Regarding Sale of Securities

Core Viewpoint - Azitra, Inc. has refuted claims regarding a false report of a $44 million registered direct offering, urging stakeholders to rely on official communications from the company [1][2]. Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on precision dermatology, with its lead program ATR-12 targeting Netherton syndrome, a rare skin disease with no approved treatments [3]. - The ATR-12 program is currently in a Phase 1b clinical trial for adult patients with Netherton syndrome [3]. - Azitra's ATR-04 program addresses EGFR inhibitor-associated rash and has received Fast Track designation from the FDA, impacting approximately 150,000 individuals in the U.S. [3]. - The company is also advancing ATR-01, a preclinical program for ichthyosis vulgaris, with plans for an IND submission in 2026 [3]. - Azitra's proprietary platform includes a microbial library of around 1,500 bacterial strains, enhanced by AI and machine learning technologies for drug discovery [3].